PharmAust Limited

Equities

PAA

AU000000PAA1

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.375 AUD +10.29% Intraday chart for PharmAust Limited +5.63% +226.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PharmAust Submits Supporting Data to US FDA for Monepantel Orphan Drug Designation Request; Shares Down 7% MT
PharmAust Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
PharmAust Gets US FDA Guidance for Motor Neuron Disease Medication MT
PharmAust Appoints Non-Executive Director MT
PharmAust Secures Ethics Approval for Phase One Motor Neuron Disease Extension Study; Shares Rise 6% MT
PharmAust to Amend Monepantel Orphan Drug Designation Request to FDA MT
PharmAust Ties Up with Berry Consultants for Upcoming Phase 2/3 Motor Neuron Disease Trial; Shares Rise 4% MT
PharmAust Secures Meeting with US FDA for Motor Neuron Disease Drug Application; Shares Jump 9% MT
PharmAust Secures Support for Phase 2/3 Clinical Trial Grant Request MT
PharmAust Secures R&D Tax Refund for Fiscal Year 2023 MT
PharmAust Achieves 93% take Up on Options Offer MT
PharmAust to Raise AU$3.5 Million From Share Sale MT
PharmAust Concludes Phase One Study for Motor Neuron Disease Medication MT
Pharmaust Completes Dosing for All Cohort Four Patients in Phase One Study of Motor Neurone Disease; Shares Rise 3% MT
PharmAust Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023 CI
PharmAust Limited Announces Executive Changes CI
PharmAust Concludes Pharmacokinetics Study in Third Group of MND Patients MT
PharmAust Subsidiary Enters Voluntary Liquidation MT
PharmAust Doses Third Patient Group for Phase 1/2 Clinical Trial of Motor Neurone Disease Treatment MT
PharmAust Validates Suppressive Capability of Motor Neuron Disease Medication MT
Pharmaust's Beagle Patient Surpasses One Year on Monepantel Drug MT
PharmAust Doses Patients for Third Cohort of Motor Neuron Disease Trial; Shares Jump 10% MT
PharmAust Begins Cohort 3 Dosing in Phase 1/2 Trial of Motor Neuron Disease Drug MT
PharmAust Finds No Safety Issues in Monepantel Clinical Trial MT
Chart PharmAust Limited
More charts
PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.
More about the company
  1. Stock
  2. Equities
  3. Stock PharmAust Limited - Australian S.E.
  4. News PharmAust Limited
  5. Pharmaust : Files Patent Application for Using Monepantel as Antiviral Drug